Acorns Advisers’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.11M Buy
2,296
+317
+16% +$321K 0.02% 37
2025
Q4
$2.13M Sell
1,979
-17
-0.9% -$16.3K 0.02% 35
2025
Q3
$1.52M Buy
1,996
+391
+24% +$291K 0.01% 37
2025
Q2
$1.25M Buy
1,605
+366
+30% +$284K 0.01% 36
2025
Q1
$1.02M Buy
1,239
+107
+9% +$89K 0.01% 34
2024
Q4
$874K Buy
1,132
+238
+27% +$197K 0.01% 34
2024
Q3
$792K Buy
894
+215
+32% +$193K 0.01% 34
2024
Q2
$615K Buy
679
+208
+44% +$166K 0.01% 33
2024
Q1
$366K Buy
+471
New +$335K ﹤0.01% 33

Other funds holding LLY

Acorns Advisers's LLY Position: Q1 2026 in Review

Acorns Advisers increased its Eli Lilly (LLY) stake by 16% in Q1 2026, buying an estimated $321K and bringing the position to 2,296 shares worth $2.11M. The position accounts for 0.02% of the portfolio, ranked #37.

Acorns Advisers first reported a position in LLY in Q1 2024 and has held it in 9 quarters since. The position peaked at $2.13M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Acorns Advisers held 2,296 shares of Eli Lilly worth $2.11M as of Q1 2026.
  • Acorns Advisers bought 317 Eli Lilly shares in Q1 2026, an estimated $321K.
  • Eli Lilly made up 0.02% of Acorns Advisers's portfolio in Q1 2026, its #37 holding.
  • Acorns Advisers first reported a position in Eli Lilly in Q1 2024 and has held it in 9 quarters since.
  • Acorns Advisers's Eli Lilly position peaked at $2.13M in Q4 2025.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Acorns Advisers's 13F filing for Q1 2026, filed 14 May 2026.